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Mucocutaneous disease and related
clinical characteristics in hospitalized
children and adolescents with COVID-19
and multisystem inflammatory
syndrome in children
Sergey Rekhtman, MD, PharmD, MPH, Rachel Tannenbaum, BS, Andrew Strunk, MA,
Morgan Birabaharan, MD, Shari Wright, BS, and Amit Garg, MD
New Hyde Park, New York
Background: Little is known about mucocutaneous disease in acutely ill children and adolescents with
COVID-19 and multisystem inflammatory syndrome in children (MIS-C).
Objective: To characterize mucocutaneous disease and its relation to clinical course among hospitalized
patients with COVID-19 and MIS-C.
Methods: Descriptive cohort study of prospectively and consecutively hospitalized eligible patients
between May 11, 2020 and June 5, 2020.
Results: In COVID-19 patients, 4 of 12 (33%) had rash and/or mucositis, including erythema, morbilliform
pattern, and lip mucositis. In MIS-C patients, 9 of 19 (47%) had rash and/or mucositis, including erythema,
morbilliform, retiform purpura, targetoid and urticarial patterns, along with acral edema, lip mucositis,
tongue papillitis, and conjunctivitis. COVID-19 patients with rash had less frequent respiratory symptoms,
pediatric intensive care unit admission, invasive ventilation, and shorter stay versus COVID-19 patients
without rash. MIS-C patients with rash had less frequent pediatric intensive care unit admission, shock,
ventilation, as well as lower levels of C-reactive protein, ferritin, D-dimer, and troponin (vs MIS-C without
rash). Neutrophil-to-lymphocyte ratio was similar for patients with and without rash in both groups. None
of the MIS-C patients met criteria for Kawasaki disease.
Limitations: Small sample sizes.
Conclusions: Mucocutaneous disease is common among children and adolescents with COVID-19 and
MIS-C. Laboratory trends observed in patients with rash may prognosticate a less severe course. ( J Am Acad
Dermatol 2021;84:408-14.)
Key words: COVID-19; Kawasaki; MIS-C; multisystem inflammatory syndrome in children; pediatrics;
prevalence; rash; SARS-CoV-2.

INTRODUCTION
COVID-19 has variability within its constellation
of findings among children and adolescents.1-5 In

addition to fever and respiratory symptoms, pediatric
patients infected with SARS-CoV-2, the pathogen in
COVID-19, also get eruptions and mucositis. Yet,
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little is understood about the morphologic spectrum
finding was pre-existing or likely to be unrelated to
of mucocutaneous disease and its relation to outSARS-CoV-2 infection. Examples included observacomes among acutely ill children and adolescents
tions of atopic eczema, furunculosis, and scar. All
with COVID-19, or its presumed sequela, multipatients who had mucocutaneous manifestations
system inflammatory syndrome in children (MIS-C).
without an otherwise known etiology were considThe New York metropolitan area was an epicenter
ered to have a COVID-19-related rash.
for the pandemic in the United States,6 which proFor their description, patients with COVID-19 and
vided an opportunity to charMIS-C were further stratified
acterize
mucocutaneous
according to presence of at
CAPSULE SUMMARY
disease in pediatric hospitalleast one COVID-19erelated
ized patients with COVID-19
rash. We categorized COVIDLittle is known about the morphologic
and MIS-C. The purpose of
19 and MIS-C patients sepaspectrum of mucocutaneous disease and
this study was to estimate
rately because these diseases
its relation to clinical course in acutely ill
prevalence of integumentary
have different clinical charchildren with COVID-19 or multisystem
findings in hospitalized paacteristics
and
disease
inflammatory syndrome in children
tients with COVID-19 and
courses and because MIS-C
(MIS-C).
MIS-C, characterize their
is considered to be a later,
morphologic patterns, evalnoninfectious complication
This study highlights novel
uate whether rash prognostiof COVID-19.
mucocutaneous observations associated
cates clinical course, and
with SARS-CoV-2 infection, which may
determine how closely feaDATA ANALYSIS
support recognition of infection and its
tures in MIS-C align with
Given the anticipated
potential relevance to prognosis and the
Kawasaki disease (KD).
sample
size, and consedevelopment of diagnostic criteria for
quently
low
statistical power,
MIS-C.
the
intent
of
our analysis was
METHODS
descriptive
and hypothesis
This study was performed
generating.
Medians
(interquartile
range [IQR])
at Cohen Children’s Hospital (Northwell Health), a
were
used
to
describe
continuous
variables,
and
tertiary hospital located in Queens, New York. The
frequencies
(percentages)
were
used
to
describe
study sample consisted of all hospitalized patients
categorical variables. This study was approved by
between May 11, 2020 and June 5, 2020 who were
the institutional review board at the Feinstein
18 years and younger and who were suspected of
Institutes of Medical Research at Northwell Health.
having COVID-19 or MIS-C. Criteria for confirming
the diagnosis of MIS-C included age less than
RESULTS
21 years, fever for 24 hours or more, clinically severe
Of 39 hospitalized pediatric patients identified as
illness requiring hospitalization, multisystem organ
possible
COVID-19 or MIS-C cases during the study
involvement, no alternative plausible diagnosis, and
period,
31
were eligible for inclusion. Six patients did
exposure to a suspected or confirmed COVID-19
not
test
positive
for SARS-CoV-2 by PCR and were
case or positive SARS-CoV-2 infection by polymerase
7
also
ruled
out
for
MIS-C prior to discharge. Others
chain reaction (PCR)/serology testing. The sample
excluded
were
1
child
whose family deferred skin
was limited to patients who had (1) diagnosis of MISexamination
and
1
newborn
having limb necrosis
C based on all 6 criteria above, and this group
with negative SARS-CoV-2 PCR and IgM antibody
comprised the MIS-C cohort or (2) positive COVIDwho was felt to have fetal compartment syndrome.
19 PCR test among those not meeting the definition
Demographic characteristics for 12 patients classified
of MIS-C, and this group comprised the COVID-19
as COVID-19 and 19 patients classified as MIS-C are
cohort.
listed in Table I.
Consecutive prospective skin examinations were
performed for eligible patients, and photographs of
COVID-19 cohort
mucocutaneous findings were taken as part of their
In patients with COVID-19, 4 of 12 (33%) had rash
care. Morphologic patterns and locations of rash
and/or mucositis (Supplemental Fig 1; available at:
were assessed based on photographs collected
https://data.mendeley.com/datasets/wrzffv27cx/1).
during clinical evaluation and were independently
Those with rash were younger (Table I). Only 3
classified by two raters. Differing classifications were
of 12 (25%) were febrile ($100.48F) during
adjudicated via discussion. For each patient, raters
hospitalization.
also determined whether each mucocutaneous
d

d
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Abbreviations used:
IQR:
KD:
MIS-C:
PCR:

interquartile range
Kawasaki disease
multisystem inflammatory syndrome in
children
polymerase chain reaction

Type and frequencies of morphologic patterns
observed in patients with COVID-19 are described in
Table I. None of the hospitalized COVID-19 patients
with rash had pernio-like lesions of the toes or
fingers, and none had conjunctivitis. Locations and
frequencies of mucocutaneous eruptions in patients
with COVID-19 are described in Fig 1.
Compared with COVID-19 patients without rash,
those with rash were observed to have less frequent
respiratory symptoms, admission to the pediatric
intensive care unit, ventilation, and shorter length of
hospital stay. Maximum neutrophil-to-lymphocyte
ratio (NLR) observed during hospitalization was
similar for patients with and without rash (Table I).

MIS-C COHORT
In patients with MIS-C, 9 of 19 (47%) had rash
and/or mucositis. (Fig 2; Supplemental Fig 2;
available at: https://data.mendeley.com/datasets/
wrzffv27cx/1). All 19 patients (100%) were febrile
during hospitalization.
Morphologic patterns were heterogeneous (Table
I). Lip fissuring or cracking was present in 44% (4 of
9), whereas papillitis of the tongue was present in
22% (2 of 9). Conjunctivitis was present in 22% (2 of
9) of patients with rash. Locations and frequencies of
mucocutaneous eruptions in patients with MIS-C are
described in Fig 1.
Compared with MIS-C patients without rash,
those with rash were observed to have less frequent
pediatric intensive care unit admission, shock, and
requirement for invasive mechanical ventilation.
Patients with rash also had lower levels of inflammatory markers. Maximum NLR observed during
hospitalization was similar for patients with and
without rash (Table II).
Among the 19 patients with MIS-C, none met 2017
American Heart Association criteria for KD.8 With
requirement for fever of at least 5 consecutive days in
the stem, only 1 (5.3%) patient met at least 3 of 5
criteria and only the same patient (1/19; 5.3%) met at
least 2 of 5 criteria. With inclusion of coronary
aneurysm as an additional sub-criterion, still none
met at least 4 of 6 criteria for KD diagnosis. In this
expanded construct, 1 (5.3%) patient met at least 3 of
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6 criteria and only 2 (10.5%) patients met at least 2 of
6 criteria. Among the 19 MIS-C patients, 5 (26.3%)
had fever for 5 or more days, 2 (10.5%) had cervical
lymphadenopathy, 2 (10.5%) had edema or erythema of hands or feet, and 2 (10.5%) had a
morbilliform or erythema-multiformeelike eruption.

DISCUSSION
Although presence of rash in MIS-C patients has
been reported,9-11 morphologic characterization of
mucocutaneous eruptions in hospitalized pediatric
patients with COVID-19 and MIS-C is otherwise
absent to date. In this analysis, we estimated prevalence of rash and/or mucositis among hospitalized
pediatric patients with COVID-19 and MIS-C. We
have characterized morphologic features and distributions of these eruptions, and we distinguished
subtypes that occurred only in MIS-C patients. We
observed that presence of rash appears to predict a
less-severe clinical course. Finally, we observed that
MIS-C and KD might be more dissimilar than
presently postulated.
Although disease-defining integumentary patterns did not emerge in either group, some patterns
of mucocutaneous disease appeared to have distinguished MIS-C from COVID-19. Retiform purpura,
targetoid, urticarial, acral edema or erythema, papillitis of the tongue, and conjunctivitis were observed
only among MIS-C patients. The observation of
unilateral retiform purpura of the arm in a patient
suggests potential for endothelial cell involvement or
injury of cutaneous vessels by the virus or the
presence of coagulopathy induced by the infection.
Vessel involvement through endothelial cell infection of the kidney and lung in adults has been
seen,12,13 and this phenomenon warrants further
study in children.
Presence of nonspecific erythema, morbilliform
eruption, or lip mucositis did not distinguish COVID19 and MIS-C. Pernio-like patches and plaques on
the fingers or toes were not observed in either group,
which reinforces the suggestion that patients with
this presentation tend to have mild disease course.14
Almost all hospitalized COVID-19 patients with
rash had involvement of at least the face. Rash
among MIS-C patients was most often peripherally
distributed. Although lips were frequently involved
in MIS-C patients, tongue and eye involvement were
less frequent. Continued localization of mucocutaneous disease in COVID-19 and MIS-C may identify
distinct patterns that differentiate the 2 conditions.
Several clinical and laboratory indicators suggested that pediatric patients with COVID-19 and
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Table I. Demographics and characteristics of mucocutaneous disease

Characteristic

Age
Male sex (%)
Race*
African American
Asian
White
Other/multiracial
Cutaneous morphologic patterns
Nonspecific erythema
Morbilliform
Retiform purpura
Targetoid
Urticarial
Edema (acral)
Pernio-like lesions
Mucositis
Lip cracking or fissuring
Papillitis of tongue
Conjunctivitis

COVID-19 with
mucocutaneous
disease
n=4

COVID-19 without
mucocutaneous
disease
n=8

MIS-C with
mucocutaneous
disease
n=9

MIS-C without
mucocutaneous
disease
n = 10

5 (1.75, 10)
1 (25)

8 (7, 10)
7 (78)
n=8
4 (50)
1 (13)
1 (13)
2 (25)

10.5 (10, 13)
6 (60)
n=8
1 (13)
1 (13)
1 (13)
5 (63)

0
0
0
4

(0)
(0)
(0)
(100)

10 (7.25, 16)
5 (63)
n=7
1 (14)
1 (14)
0 (0)
5 (71)

3
1
0
0
0
0
0

(75)
(25)
(0)
(0)
(0)
(0)
(0)

d
d
d
d
d
d
d

3
1
1
1
1
1
0

(33)
(11)
(11)
(11)
(11)
(11)
(0)

d
d
d
d
d
d
d

1 (25)
0 (0)
0 (0)

d
d
d

4 (44)
2 (22)
2 (22)

d
d
d

Note. Percentages may not sum to 100 due to rounding. Continuous variables are presented as median (IQR). Categorical variables are
presented as frequency (percent).
*Self-reported race.

MIS-C with rash may have less severe disease course.
MIS-C patients with rash may have a modified and/or
muted cytokine response, which preferentially involves the integument and which may result in a
less severe course. Whether presence of rash in
COVID-19 and MIS-C can predict prognosis in
children and adolescents and the basis for preferential involvement of skin warrants further study.
The NLRs were similar between COVID-19 patients with and without rash and between MIS-C
patients with and without rash. We did observe,
however, higher NLR in MIS-C patients compared
with COVID-19 patients, and this may prove to be a
useful differentiating marker. In adults, NLR has been
observed to distinguish mild from severe cases of
COVID-19.15-17
There are shared features between MIS-C and KD,
including presence of mucocutaneous disease,
although the distinction between MIS-C and KD
remains uncertain.18 None of the MIS-C in our
sample met criteria for KD, and few met partial
criteria, even when criteria were expanded to
include coronary aneurysm. Only 5 patients met
criterion for fever of greater than 5 consecutive days,
and few had lymphadenopathy or edema/erythema
of hands or feet. Although there may exist some

overlapping features between MIS-C and KD, our
observations suggest that MIS-C may warrant development of distinct criteria, which should include
broadening the morphologic patterns of mucocutaneous disease observed.
Here we provided detailed morphologic characterization of mucocutaneous findings in prospectively and consecutively examined patients with
confirmed diagnoses of COVID-19 and MIS-C.
Limitations to this study include the fact that most
pediatric patients with COVID-19 have a course that
does not require hospitalization, and there were
fewer hospitalized cases of MIS-C in mid May and
June of 2020 in the New York metropolitan area. As
such, we had inadequate power to perform hypothesis tests, and we cannot rule out that differences
observed between groups were due to chance.
However, the finding of less-severe course was
observed across several indicators among both
COVID-19 and MIS-C patients with rash. Pathology
was not obtained, as there was no clear indication
this could specify diagnoses or change the courses of
care.
Mucocutaneous disease is common among children and adolescents with COVID-19 and MIS-C.
Trends observed in pediatric patients with rash may
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Fig 1. Frequencies of children with mucocutaneous disease in COVID-19 and MIS-C by area of
involvement.

Fig 2. A and B, Mucocutaneous disease in children and adolescents with MISC-C. A, Retiform
purpura, arm. B, Targetoid erythema, arm.

suggest a less-severe clinical course, although confirmatory studies are required to assess the generalizability of these observations. This study highlights
several novel observations in hospitalized children
and adolescents with COVID-19 and MIS-C, many of

which will support the research agenda to further
characterize mucocutaneous disease associated with
SARS-CoV-2, to recognize its potential relevance in
prognosticating disease courses, and to develop
diagnosis criteria for MIS-C.
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Table II. Clinical characteristics of patients with and without mucocutaneous disease
COVID-19 with
mucocutaneous
disease
n=4

Fever, peak
Fever $5 consecutive days
Laterocervical lymphadenopathy
Respiratory symptoms
Gastrointestinal symptoms
Shock
Coronary aneurysm or pericardial
effusion
Myocardial infarction
Venous thrombosis or
thromboembolism
Arterial thrombosis
Treatment with intravenous
immunoglobulin
Treatment with aspirin
Admission to pediatric
intensive care unit
Ventilation
Hospital length of stay,* days
Lymphocyte count, minimumy
Neutrophil count, maximum
Neutrophil/lymphocyte ratio,
maximum{
C-reactive protein, maximum,
mg/dL
Ferritin, maximum, ng/mL
(normal, 30-400)
Lactate dehydrogenase, maximum,
U/L (normal, 50-242)
Albumin, minimum, g/dL
(normal, 3.5-5.0)
Procalcitonin, maximum,
ng/mL (normal, 0.02-0.10)
D-Dimer, maximum, ng/mL
(normal, #229)
Fibrinogen, maximum, mg/dL
(normal, 300-520)
Troponin, maximum, ng/L
(normal, \6-14)
proBNP, maximum, pg/mL
(normal, \300)
SarsCOV2 1 PCR, %
SarsCOV2 1 IgM/IgG, %

99.8
0
0
0
3
0
0

(99.4, 100.6)
(0)
(0)
(0)
(75)
(0)
(0)

COVID-19 without
mucocutaneous
disease
n=8

99.8
0
0
3
4
1
1

(99.6, 100.3)
(0)
(0)
(38)
(50)
(13)
(13)

MIS-C with
mucocutaneous
disease
n=9

103.1
3
1
5
9
3
4

(102.9, 103.6)
(33)
(11)
(56)
(100)
(33)
(44)

MIS-C without
mucocutaneous
disease
n = 10

103.4
2
1
6
10
8
6

(103.1, 104.8)
(20)
(10)
(60)
(100)
(80)
(60)

0 (0)
0 (0)

0 (0)
0 (0)

0 (0)
0 (0)

0 (0)
0 (0)

1 (13)
0 (0)

0 (0)
9 (100)

0 (0)
10 (100)

0 (0)
0 (0)

1 (13)
3 (38)

9 (100)
3 (33)

9 (90)
9 (90)

0
2.5
1.23
4.20
0.84

(0)
(2, 6)
(0.34, 4.70)z
(0.31, 8.02)z
(0.58, 6.52)z

1
5
1.50
7.62
3.51

(13)
(1.5, 17)
(0.97, 2.17)
(3.39, 11.57)
(1.76, 8.69)

1
7
0.61
17.00
15.01

(13)
(5, 9)
(0.48, 0.93)
(10.26, 19.37)
(8.62, 17.18)

0 (0)
0 (0)

4
7
0.58
18.85
13.21

(40)
(5, 10)
(0.44, 0.87)
(14.31, 24.22)
(8.66, 23.04)

1.4 (1.2, 3.9)z

1.6 (0.8, 2.2)x

731 (93, 3024)

200 (144, 369)x

578 (370, 1091)

1457 (808, 2214)

263 (197, 465)

257 (202, 650)z

346 (233, 533)

322 (260, 415)

2.6 (2.1, 2.8)

2.1 (1.8, 2.7)

3.7 (3.5, 3.8)

3.5 (3.3, 4.1)

15.2 (15, 17)

26.3 (19.1, 28.2)

0.22 (0.17, 0.53)z

0.13 (0.08, 0.24)z

6.24 (2.00, 14.44)

9.4 (3.4, 29.0)

570 (439, 952)

300 (263, 904)

1492 (1287, 2681)

4147 (2538, 5011)

525 (486, 577)

510 (506, 535)

718 (698, 884)

802 (713, 908)

5 (5, 15)z

8 (5, 11)x

172 (21, 326)

545 (10, 909)z

4 (100)
2 (50)

8 (100)
2 (25)

18 (8, 38)
3946 (3351, 6455)
3 (33)
7 (78)

70 (17, 114)
5065 (2754, 10980)
2 (20)
10 (100)

proBNP, N-terminal pro b-type natriuretic peptide.
*Median length of stay (25th percentile, 75th percentile) calculated using the Kaplan-Meier survival estimate to account for patients who
were not discharged as of the date of chart abstraction.
y
Maximum and minimum refer to each patient’s maximum or minimum value during hospitalization. The summary measure represents the
median across all of the individual patient maximums/minimums. Continuous variables are presented as median (IQR). Categorical variables
are presented as frequency (percent).
z
Based on 3 non-missing values. Raw data values are reported, rather than median and IQR.
x
Based on 4 non-missing values.
{
Ratio was calculated by dividing the neutrophil count by the lymphocyte count from the same test result. The maximum ratio during
hospitalization for each patient was then selected and summarized by group using the median and IQR.
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